NEOG NEOGEN CORP

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • Regulatory risk from Australian and New Zealand regulators reviewing $160M Genomics business sale to Zoetis, delaying expected closing beyond H1 FY2027
• • Geopolitical exposure with 51.2% revenue from international markets facing risks including Russia-Ukraine conflict sanctions and Middle East tensions impacting supply and costs
• • Operational risk in ongoing transition of Petrifilm manufacturing from 3M to Neogen with expected completion in FY2027, incurring duplicative costs and regulatory approvals
• • Competitive risk from AI and emerging technologies disrupting animal and food safety markets, requiring effective integration and risk management to maintain competitive position
• • Financial risk from $450M new senior secured term loan and $100M drawn on $250M revolving credit, with covenants restricting investments, dividends, and debt that may limit financial flexibility

Management Discussion & Analysis

• • Revenue $870.4M, down 3% YoY ($24.3M decrease) due to $55.6M discontinued product lines partially offset by $17.3M organic growth
• • Gross margin 46.9% vs 47.1% YoY, slight decline due to volume decreases and duplicative costs; Food Safety operating income $63.4M vs loss $(985.7)M
• • Animal Safety segment revenues $229.3M, down 11% YoY; operating income $24.5M vs $7.3M, best margin improvement; Food Safety segment best revenue performer
• • Operating cash flow $83.2M, up $25.0M; investing cash inflow $70.5M due to $121.7M sale proceeds; financing cash outflow $99.4M driven by debt repayments
• • Management plans growth via innovation, commercial excellence, cost management; sale of Genomics business pending; supply chain and tariff risks to persist in FY2027

Business Overview

• • Core business model: Develop, manufacture, and market food and animal safety diagnostic products, veterinary instruments, pharmaceuticals, and related services worldwide
• • Significant divestiture: Announced agreement to sell Genomics business to Zoetis Inc. for $160 million, pending regulatory approval and closing by mid-fiscal 2027
• • Strategic shift: Divested global Cleaners and Disinfectants business in July 2025, streamlining focus on core Food Safety and Animal Safety segments
• • Employee count: 2,636 total employees globally as of May 31, 2026, with 817 in sales and marketing and 89 in R&D
• • Noteworthy fact: Sales outside the U.S. accounted for 51.2% of total revenues, showing continued international growth and geographic diversification

What are the latest NEOG SEC filings in 2026?

NEOGEN CORP (NEOG) has filed a 10-K annual report on July 30, 2026, a 10-Q quarterly report on April 9, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did NEOG file its most recent 10-K annual report?

NEOGEN CORP (NEOG) filed its most recent 10-K annual report on July 30, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view NEOG 10-Q quarterly reports?

NEOGEN CORP (NEOG)'s most recent 10-Q quarterly report was filed on April 9, 2026. SignalX displays every NEOG 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has NEOG filed recently?

NEOGEN CORP (NEOG)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find NEOG insider trading activity (Form 4)?

SignalX aggregates every NEOG Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does NEOG file with the SEC?

NEOGEN CORP (NEOG) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NEOG filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for NEOGEN CORP (NEOG).

What is NEOG's SEC CIK number?

NEOGEN CORP (NEOG)'s SEC CIK (Central Index Key) number is 711377. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 711377 to look up all NEOG filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find NEOG return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from NEOGEN CORP (NEOG) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.